A 69-year-old white woman presented to the emergency department after returning to the United Kingdom from Malaga, Spain, 4 days previously. She complained of a 2-week history of widespread severe myalgias, a 3-day history of nonproductive cough, and dyspnea on exertion rapidly progressing to dyspnea at rest on the day before admission. She denied coryzal symptoms and visual or auditory changes. Medical history included Graves disease under remission and anxiety. Her only medication was bisoprolol. Examination revealed decreased breath sounds bilaterally but was otherwise unremarkable. Her temperature was 36°C; heart rate, 98 beats per minute; blood pressure, 127/76 mm Hg; respiratory rate, 36 breaths per minute; and the oxygen saturation, 80% on ambient air. She was promptly referred to the general medicine team as presumed COVID-19.

Initial laboratory tests revealed a decreased hemoglobin level of 77 g/L (reference range, 135--175 g/L) and an elevated leukocyte level with neutrophilia, lymphopenia, and eosinophilia. C-reactive protein was elevated at 289 mg/L. Urine dip was unremarkable, with no protein or blood. A chest radiograph revealed significant bilateral perihilar patchy air space shadowing, more prominent on the right, occupying at least 50% to 75% of the lung volume (Figure). Chest computed tomography (CT) was then performed, which showed extensive and dense bilateral consolidation in a predominantly perihilar distribution, with relative sparing of the peripheries and lung bases. The consolidation appeared to be most dense in the peribronchial regions. Discrete peripheral opacities were seen in both lungs, with mild interlobular septal thickening and small bilateral pleural effusions. While awaiting results of the nasal swab SARS-CoV-2 reverse transcription polymerase chain reaction, the patient received supportive treatment with oxygen and intravenous fluids. During this time, the possibility of a parasitic infection or vasculitic process was raised given the eosinophilia, dense opacities, and pleural effusions on imaging. A parasitic screen was unremarkable, and additional blood tests showed a strongly positive proteinase 3 antibody at 127 U/L (reference range, 0--20 U/L) and antineutrophil cytoplasmic antibody in a c-ANCA pattern. The initial SARS-CoV-2 test was negative, as well as repeat testing 24 hours later. After consultation with the rheumatology team, a diagnosis of ANCA-associated vasculitis was made based on the positive serology and CT findings indicative of pulmonary hemorrhage. The patient was started on 500 mg of intravenous methylprednisolone daily for 3 days, with marked symptomatic improvement and in oxygen saturation levels. She was then switched to 60 mg of oral prednisone, as well as intravenous immunoglobulin and rituximab, in order to rapidly taper steroids in light of the pandemic.
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This patient presented with a clinical and imaging picture highly suspicious for COVID-19. Although this diagnosis is highly likely during the ongoing pandemic, some of her laboratory results and CT findings were atypical for COVID-19. Typical CT findings in COVID-19 include bilateral ground-glass opacities with a prominent distribution in the posterior and peripheral parts of the lungs.^[@bib1]^ Pleural effusions in COVID-19 are an uncommon finding, seen in only approximately 5% of cases.^[@bib2]^ Furthermore, the dense opacities on chest CT in our patient were consistent with the pulmonary hemorrhage seen in vasculitis. Although tempting to attribute suggestive findings to COVID-19, clinicians must also remember to consider other etiologies in the context of atypical results.
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